SEC 13F Intelligence

Managers / Q1 2026

Privium Fund Management B.V.

CIK 0001795097 · GUSTAV MAHLERPLEIN 3, AMSTERDAM, P7, 1082 MS · 31 20 462 6644

Reported Value
$480M
Q1 2026
Positions
60
Filings on Record
20
2019–present window
Filed
May 5, 2026
original filing

Summary

Privium Fund Management B.V. reported $480M in U.S.-listed holdings across 60 positions for Q1 2026.

Its largest position, TSLA, represents 17.2% of the portfolio.

Compared with Q4 2025, the fund opened 7 new positions and exited 4.

Portfolio Metrics

Turnover
+6.4%
vs prior filed quarter
Top-10 Concentration
+64.0%
share of reported value
Largest Position
+17.2%
Tesla
New / Exited
7 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’21: $504MQ4 ’21Q1 ’22: $452MQ2 ’22: $302MQ3 ’22: $275MQ3 ’22Q4 ’22: $264MQ1 ’23: $298MQ2 ’23: $347MQ2 ’23Q3 ’23: $336MQ4 ’23: $359MQ1 ’24: $374MQ1 ’24Q2 ’24: $392MQ3 ’24: $402MQ4 ’24: $442MQ4 ’24Q1 ’25: $384MQ2 ’25: $464MQ3 ’25: $556MQ3 ’25Q4 ’25: $543MQ1 ’26: $480Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.6%Other: 15.3%ADR: 4.1%ETP: 0.0%
  • Common Stock · 80.6% · $387M
  • Other · 15.3% · $74M
  • ADR · 4.1% · $20M
  • ETP · 0.0% · $208,521

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ESPRESPERION THERAPEUTICS INC NENEW+3.30M3.30M+$9M$9M
BMRNBIOMARIN PHARMACEUTICAL INCNEW+92.3K92.3K+$5M$5M
DNLIDENALI THERAPEUTICS INCNEW+254.9K254.9K+$5M$5M
ALNYALNYLAM PHARMACEUTICALS INCNEW+12.2K12.2K+$4M$4M
MOHMOLINA HEALTHCARE INCNEW+8.1K8.1K+$1M$1M
BTOB2GOLD CORPNEW+96.5K96.5K+$437,041$437,041
PAASPAN AMERN SILVER CORPNEW+3.9K3.9K+$213,057$213,057
MRKMERCK & CO INCSOLD OUT−36.6K0−$4M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TSLATESLA INChistory →COM17.18%$83M222.0K
2SHOPSHOPIFY INChistory →CL A SUB VTG SHS10.05%$48M407.0K
3SPOTIFY TECHNOLOGY S ASHS6.76%$32M67.0K
4PLTRPALANTIR TECHNOLOGIES INChistory →CL A6.09%$29M200.0K
5AMZNAMAZON COM INChistory →COM5.42%$26M125.0K
6ARWRARROWHEAD PHARMACEUTICALS INhistory →COM4.79%$23M366.9K
7ISIIONIS PHARMACEUTICALS INChistory →COM4.53%$22M290.0K
8LMNDLEMONADE INChistory →COM3.33%$16M255.3K
9NVDANVIDIA CORPORATIONhistory →COM2.94%$14M81.0K
10COINCOINBASE GLOBAL INChistory →COM CL A2.87%$14M79.0K
11AMDADVANCED MICRO DEVICES INChistory →COM2.63%$13M62.0K
12ASTSAST SPACEMOBILE INChistory →COM CL A2.50%$12M145.0K
13SESEA LTDhistory →SPONSORD ADS2.38%$11M138.0K
14IREN LIMITEDORDINARY SHARES2.28%$11M320.1K
15AXSMAXSOME THERAPEUTICS INC.history →COM2.07%$10M58.7K
16ESPRESPERION THERAPEUTICS INC NEhistory →COM1.88%$9M3.30M
17PROQR THRAPEUTICS N VSHS EURO1.84%$9M5.47M
18BIIBBIOGEN INChistory →COM1.67%$8M43.8K
19UNIQURE NVSHS1.66%$8M486.5K
20RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.59%$8M364.8K
21ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM1.57%$8M321.0K
22BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.09%$5M92.3K
23VRTXVERTEX PHARMACEUTICALS INChistory →COM1.06%$5M11.4K
24DNLIDENALI THERAPEUTICS INChistory →COM1.02%$5M254.9K
25UROGEN PHARMA LTDCOM0.89%$4M238.1K
26ALNYALNYLAM PHARMACEUTICALS INCCOM0.84%$4M12.2K
27VRDNVIRIDIAN THERAPEUTICS INCCOM0.71%$3M173.5K
28KRYSKRYSTAL BIOTECH INCCOM0.60%$3M11.2K
29ABEVAMBEV SASPONSORED ADR0.58%$3M948.6K
30ZLABZAI LAB LTDADR0.52%$2M132.2K
31BNTXBIONTECH SESPONSORED ADS0.50%$2M27.0K
32ENGENE HOLDINGS INCCOM0.50%$2M352.1K
33CRISPR THERAPEUTICS AGNAMEN AKT0.42%$2M42.9K
34MEIRAGTX HLDGS PLCCOM0.38%$2M212.1K
35WAVE LIFE SCIENCES LTDSHS0.36%$2M241.0K
36STOKSTOKE THERAPEUTICS INCCOM0.34%$2M50.0K
37FDMT4D MOLECULAR THERAPEUTICS INCOM0.33%$2M170.3K
38BEAMBEAM THERAPEUTICS INCCOM0.32%$2M64.0K
39MRNAMODERNA INCCOM0.32%$2M30.0K
40PFEPFIZER INCCOM0.31%$1M52.7K
41LXEOLEXEO THERAPEUTICS INCCOM0.24%$1M205.0K
42RNACCARTESIAN THERAPEUTICS INCCOM NEW0.23%$1M179.1K
43MOHMOLINA HEALTHCARE INCCOM0.23%$1M8.1K
44SRPTSAREPTA THERAPEUTICS INCCOM0.21%$1M46.0K
45SLBSLB LIMITEDCOM STK0.20%$948,19718.5K
46RCKTROCKET PHARMACEUTICALS INCCOM0.18%$866,883242.1K
47HIMSHIMS & HERS HEALTH INCCOM CL A0.17%$830,40040.0K
48TSHATAYSHA GENE THERAPIES INCCOM SHS0.17%$813,093181.9K
49NOVNOV INCCOM0.16%$790,50942.0K
50TRANSOCEAN LTDREGISTERED SHS0.15%$706,785106.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$480M60May 5, 202613F-HRchanges · EDGAR ↗
Q4 2025$543M57Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$556M59Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$464M55Jul 30, 202513F-HRchanges · EDGAR ↗
Q1 2025$384M56May 9, 202513F-HRchanges · EDGAR ↗
Q4 2024$442M64Feb 11, 202513F-HRchanges · EDGAR ↗
Q3 2024$402M82Nov 1, 202413F-HRchanges · EDGAR ↗
Q2 2024$392M129Aug 1, 202413F-HRchanges · EDGAR ↗
Q1 2024$374M117Apr 30, 202413F-HRchanges · EDGAR ↗
Q4 2023$359M114Feb 26, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$336M115Nov 6, 202313F-HRchanges · EDGAR ↗
Q2 2023$347M124Jul 26, 2023RESTATEMENTchanges · EDGAR ↗
Q1 2023$298M126May 3, 202313F-HRchanges · EDGAR ↗
Q4 2022$264M150Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$275M226Nov 3, 202213F-HRchanges · EDGAR ↗
Q2 2022$302M252Jul 28, 202213F-HRchanges · EDGAR ↗
Q1 2022$452M279May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$504M253Feb 9, 202213F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.